146 related articles for article (PubMed ID: 37933640)
21. Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways.
Zhou J; Dong C; Tan J; Wang G; Li Z; Li S; He Z
Apoptosis; 2024 Feb; 29(1-2):121-141. PubMed ID: 37848672
[TBL] [Abstract][Full Text] [Related]
22. Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression.
Li X; Chen X; Fu C; Xie M; Ouyang S
Chemotherapy; 2023; 68(3):119-130. PubMed ID: 36657426
[TBL] [Abstract][Full Text] [Related]
23. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
[TBL] [Abstract][Full Text] [Related]
24. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
27. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
28. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
29. The Role of Cyanidin-3-
Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
[TBL] [Abstract][Full Text] [Related]
30. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
[TBL] [Abstract][Full Text] [Related]
31. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
[TBL] [Abstract][Full Text] [Related]
32. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.
Zhang B; Chan SH; Liu XQ; Shi YY; Dong ZX; Shao XR; Zheng LY; Mai ZY; Fang TL; Deng LZ; Zhou DS; Chen SN; Li M; Zhang XD
J Cell Mol Med; 2021 Sep; 25(18):8836-8849. PubMed ID: 34378321
[TBL] [Abstract][Full Text] [Related]
33. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
[TBL] [Abstract][Full Text] [Related]
34. SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
Feng D; He J; Yuan M; Chen Q; Zeng X; Zhou Q; Wu J; Han B
Biofactors; 2023; 49(6):1158-1173. PubMed ID: 37338025
[TBL] [Abstract][Full Text] [Related]
35. TWIST1 Promotes Colorectal Carcinoma Stemness and Oxaliplatin Resistance by Activating Microfibrillar-Associated Protein 2.
Liu Y; Chen M; Wu B
Assay Drug Dev Technol; 2023 Jul; 21(5):202-211. PubMed ID: 37428562
[TBL] [Abstract][Full Text] [Related]
36. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
37. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
38. Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma.
Zhou W; Fang C; Zhang L; Wang Q; Li D; Zhu D
Biochem Biophys Res Commun; 2020 Apr; 524(3):582-588. PubMed ID: 32029274
[TBL] [Abstract][Full Text] [Related]
39. The secretogranin II gene is a signal integrator of glutamate and dopamine inputs.
Iwase K; Ishihara A; Yoshimura S; Andoh Y; Kato M; Seki N; Matsumoto E; Hiwasa T; Muller D; Fukunaga K; Takiguchi M
J Neurochem; 2014 Jan; 128(2):233-45. PubMed ID: 24111984
[TBL] [Abstract][Full Text] [Related]
40. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
Yu M; Wang H; Zhao W; Ge X; Huang W; Lin F; Tang W; Li A; Liu S; Li RK; Jiang SH; Xue J
Theranostics; 2022; 12(9):4386-4398. PubMed ID: 35673560
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
